Solid and nanostructured lipid carriers for plant-derived neuroprotective agents: Advances and future perspectives

Basit Öğe Kaydı
dc.authorid0000-0002-5829-7869
dc.authorid0000-0002-0085-7552
dc.authorid0000-0002-8506-2723
dc.authorid0000-0001-8799-6565
dc.authorid0000-0002-0138-2480
dc.authorid0000-0001-6212-2706
dc.contributor.authorKüpeli, Esra
dc.contributor.authorMancak, Methiye
dc.contributor.authorÇakırlı, Egemen
dc.contributor.authorBardakçı, Hilal
dc.contributor.authorAvcı, Tuğba Buse
dc.contributor.authorÖzdemir, Samet
dc.date.accessioned2026-11-06T13:54:33Z
dc.date.available2026-11-06T13:54:33Z
dc.date.issued2026
dc.departmentFakülteler, Eczacılık Fakültesi, Eczacılık Teknoloji Bölümü, Farmasötik Teknoloji Ana Bilim Dalı
dc.description.abstractNeurodegenerative disorders, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD), continue to pose a substantial therapeutic challenge, largely due to progressive neuronal degeneration and the limited effectiveness of currently available treatments. Plant-derived bioactive compounds—including poly phenols, alkaloids, terpenoids, and flavonoids—have shown notable neuroprotective properties. However, their clinical use remains constrained by low bioavailability and limited ability to cross the blood–brain barri er (BBB). Lipid-based nanocarrier systems, especially solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), have emerged as promising alternatives for improving delivery efficiency. This review evaluates recent advances in SLN and NLC formulations developed for phytochemical delivery in neuro degenerative conditions, focusing on formulation approaches, production methods, and the physicochemical factors that govern system performance. Preclinical findings consistently indicate enhanced solubility, im proved stability, and more effective brain targeting with these systems. Even so, several challenges continue to impede their clinical translation. In particular, issues related to formulation reproducibility, scalability of production, and long-term safety remain unresolved. Alternative administration routes such as intranasal de livery offer a potential strategy to bypass the BBB, although their practical feasibility still requires further confirmation. SLN- and NLC-based systems offer a promising approach, although their clinical development is still ongoing. Future efforts should focus on establishing standardized formulation protocols, conducting rigorous in vivo studies, and ensuring alignment with regulatory requirements to facilitate successful clinical translation.
dc.identifier.citationKüpeli, E., Mancak, M., Çakırlı, E., Bardakçı, H., Avcı, T. B., & Özdemir, S. (2026). Solid and nanostructured lipid carriers for plant-derived neuroprotective agents: Advances and future perspectives. Current Pharmaceutical Design, pp. 1-22. https://doi.org/10.2174/0113816128509583260914134550
dc.identifier.doi10.2174/0113816128509583260914134550
dc.identifier.endpage22
dc.identifier.issn1381-6128
dc.identifier.issn1873-4286
dc.identifier.pmidPMID: 42813641
dc.identifier.scopus2-s2.0-105052277768
dc.identifier.scopusqualityQ2
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.2174/0113816128509583260914134550
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1699
dc.identifier.wosWOS:001890973300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorÖzdemir, Samet
dc.institutionauthorid0000-0001-6212-2706
dc.language.isoen
dc.publisherBentham Science Publishers
dc.relation.ispartofCurrent Pharmaceutical Design
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectSolid Lipid Nanoparticles
dc.subjectNanostructured Lipid Carriers
dc.subjectPhytochemicals
dc.subjectNeurodegenerative Disorders
dc.subjectAlzheimer’s Disease
dc.subjectParkinson’s Disease
dc.subjectBlood–Brain Barrier
dc.titleSolid and nanostructured lipid carriers for plant-derived neuroprotective agents: Advances and future perspectives
dc.typeReview Article
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Tam Metin / Full Text.pdf
Boyut:
4.88 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Farmasötik Teknoloji Ana Bilim Dalı Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu